8-K: Surmodics Reports Strong Q4 Revenue Growth Amidst Pending Acquisition

Surmodics announced a 19% year-over-year increase in total revenue for the fourth quarter of fiscal year 2024, driven by strong performance in its Medical Device segment, while also reporting a net loss due to merger-related expenses.

Summary

• Surmodics reported a 19% increase in total revenue for the fourth quarter of fiscal year 2024, reaching $33.2 million, compared to $28.0 million in the same period last year.
• Excluding SurVeil drug-coated balloon (DCB) license fee revenue, total revenue increased by 17% to $31.3 million.
• The Medical Device segment saw a 22% revenue increase to $25.8 million, with product sales up by 39%.
• The In Vitro Diagnostics (IVD) segment experienced an 8% revenue increase to $7.5 million.
• For the full fiscal year 2024, total revenue was $126.1 million, a decrease of 5% compared to the previous year, which included a significant $25 million license fee.
• Excluding SurVeil DCB license fee revenue, total revenue for the full year increased by 17% to $121.0 million.
• The company reported a GAAP net loss of $(3.4) million for the quarter and $(11.5) million for the full fiscal year.
• Adjusted EBITDA was $4.4 million for the quarter and $14.7 million for the full fiscal year.
• Surmodics is being acquired by GTCR for $43.00 per share in cash, valuing the company at approximately $627 million, with the merger expected to close in the second fiscal quarter ending March 31, 2025.

Sentiment

Score: 7

Explanation: The document presents a mixed picture with strong revenue growth in Q4 and positive clinical results, but also a net loss and a pending merger with potential risks. The overall sentiment is positive due to the strong operational performance and the acquisition, but tempered by the financial losses and regulatory hurdles.

Positives

• The Medical Device segment showed strong growth, with product sales increasing by 39% in the fourth quarter.
• The Pounce XL Thrombectomy System received FDA clearance, expanding its potential market.
• The PROWL registry study demonstrated high procedural flow restoration rates with the Pounce Thrombectomy System.
• The company's adjusted EBITDA improved significantly in the fourth quarter compared to the same period last year.
• The pending acquisition by GTCR provides a clear path for shareholders to realize value at $43.00 per share.

Negatives

• The company reported a GAAP net loss of $(3.4) million for the fourth quarter and $(11.5) million for the full fiscal year.
• The full fiscal year total revenue decreased by 5% compared to the previous year, primarily due to a decrease in SurVeil DCB license fee revenue.
• Operating costs and expenses increased by 8% in the fourth quarter, driven by merger-related charges and increased sales compensation expenses.
• The company's GAAP net loss per diluted share was $(0.24) for the quarter and $(0.82) for the full fiscal year.

Risks

• The merger with GTCR is subject to regulatory approval and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
• There is a risk that the merger may not be completed within the anticipated timeframe or at all.
• The company is working to comply with the FTC's Second Request, which could delay the merger.
• The company's stock price may decline if the merger is not completed.
• The company may be required to pay a termination fee of $20.38 million if the merger agreement is terminated under certain circumstances.
• The company's business operations could be disrupted by the pending merger.

Future Outlook

Surmodics is not providing financial guidance for fiscal year 2025 due to the pending acquisition by GTCR. The merger is expected to close in the second fiscal quarter ending March 31, 2025, subject to customary closing conditions and regulatory approval.

Management Comments

• Gary Maharaj, President and CEO of Surmodics, Inc., stated that they are proud to deliver a strong conclusion to fiscal 2024, with total revenue growth in the fourth quarter of 19% year-over-year.
• He also noted that the Medical Device segment product sales growth in the fourth quarter was driven primarily by demand for their vascular interventional products, including the Pounce Thrombectomy Platform and SurVeil DCB.
• Maharaj thanked the Surmodics team for their dedication and focus in delivering strong quarterly and full-year operating results while working to comply with the FTC's Second Request.

Industry Context

Surmodics' strong fourth-quarter performance, particularly in its Medical Device segment, highlights the growing demand for advanced medical technologies in vascular intervention. The FDA clearance of the Pounce XL Thrombectomy System and positive clinical results from the PROWL registry study further solidify Surmodics' position in the market. The pending acquisition by GTCR reflects the ongoing consolidation trend in the healthcare and medical device industry, where private equity firms are increasingly investing in companies with strong growth potential and innovative technologies.

Comparison to Industry Standards

• Surmodics' 19% revenue growth in Q4 is strong compared to the average growth rate of medical device companies, which typically ranges from 5-10% annually, although some high-growth companies can exceed this.
• Companies like Medtronic and Abbott, which are major players in the medical device space, often see more moderate growth rates due to their size and market saturation, making Surmodics' growth rate notable.
• The 39% growth in Medical Device product sales is particularly impressive, indicating strong market adoption of their products, especially the Pounce Thrombectomy Platform and SurVeil DCB.
• The adjusted EBITDA of $4.4 million for the quarter, while positive, is still relatively low compared to larger, more established medical device companies, which often have EBITDA margins in the 20-30% range.
• The pending acquisition by GTCR at $43.00 per share reflects a premium over the company's recent trading price, suggesting that the private equity firm sees significant value and growth potential in Surmodics' technology and market position.
• The PROWL registry study results, with 96.8% procedural flow restoration, are very positive and compare favorably to other thrombectomy devices on the market, which often have success rates in the 80-90% range.

Stakeholder Impact

• Shareholders will receive $43.00 per share in cash upon completion of the merger with GTCR.
• Employees may experience uncertainty due to the pending acquisition.
• Customers will continue to receive Surmodics' products and services.
• Suppliers may be impacted by the change in ownership.
• Creditors will be impacted by the change in ownership and the company's debt structure.

Next Steps

• The company will continue to work to substantially comply with the FTC's Second Request.
• The company and GTCR will work towards consummating the merger in the second fiscal quarter ending March 31, 2025.
• Surmodics will continue to commercialize its SurVeil DCB, Sundance DCB, and other proprietary products.
• The company will continue to develop and market its vascular intervention products.

Key Dates

Keywords

Surmodics, Medical Devices, In Vitro Diagnostics, Thrombectomy, GTCR, Merger, FDA Clearance, Financial Results, Revenue Growth, Adjusted EBITDA